ArticlePloS one2026
The inhibitors of miR-224-5p, miR-339-5p, and miR-1198-5p improve auditory function by promoting the expression of neuritin in hearing loss mice.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSensorineural hearing loss (SNHL) is the main type of hearing impairment, and currently there is a lack of effective preventive or therapeutic drugs. Our previous research revealed that the expression of neurotrophic factor Neuritin decreased in hearing loss. After treatment with recombinant human Neuritin protein, the number of hair cells significantly increased. However, the molecular mechanism underlying the decreased expression of Neuritin in hearing loss remains unclear. Research indicates that Neuritin expression is regulated by microRNAs (miRNAs). This study aims to screen and validate the key miRNAs that regulate the expression of Neuritin and assess the feasibility of these miRNAs as therapeutic targets for SNHL.
methodsThis study utilized a mouse model of SNHL and employed high-throughput sequencing and bioinformatics analysis to screen for miRNAs that regulate the expression of neurofilament proteins in cochlear tissues. Subsequently, in vivo experiments were conducted to verify the regulatory effects of the candidate miRNAs on neurofilament proteins and to evaluate the improvement of SNHL by the corresponding miRNA inhibitors.
resultsAfter screening and identification, three miRNAs specifically inhibiting the expression of neurofilament protein were obtained, namely miR-224-5p, miR-339-5p and miR-1198-5p. The in vivo experimental results indicated that the inhibitors of the above three miRNAs had a significant improvement effect on the SNHL mouse model.
conclusionMiR-224-5p, miR-339-5p and miR-1198-5p can be involved in the pathogenesis of SNHL by regulating the expression of neurofilament proteins. Targeting these miRNAs or their inhibitors can provide new molecular targets and strategies for the prevention and treatment of SNHL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.